1909 results about "Thelial cell" patented technology

The invention belongs to the technical field of biology, and discloses a reagent combination or kit for constructing intestinal organs and application of the reagent combination or kit. According to the reagent combination or the kit, intestinal organs can be obtained from cell-derived epithelial cells obtained from a donor in a non-invasive manner, and the obtained intestinal organs can be cryopreserved and recovered and can be amplified in vitro for a long time; transcriptome characteristics are similar to those of real human small intestine tissues, and typical marker genes of various small intestine pedigree cell types are highly expressed; compared with intestinal organs obtained through induction of pluripotent stem cells, the intestinal organs have more intestinal pedigree characteristics, and the intestinal function development is more mature; after being promoted to be mature, the intestinal organ also highly expresses genes related to drug absorption and metabolism, has drug absorption capability similar to that of an immortalized intestinal cell line, but more prominently shows intestinal cell lineage characteristics, is closer to an intestinal environment in a real human body, and can be used for screening intestinal disease drugs; the intestinal barrier function is realized.

The invention relates to the technical field of antibacterial peptide application, in particular to an antibacterial peptide for inhibiting drug-resistant acinetobacter baumannii as well as a preparation method and application of the antibacterial peptide. The antibacterial peptide is cd77AHP-2, and the amino acid sequence of the antibacterial peptide is shown as SEQ ID NO.1. The antibacterial peptide cd77 obtained through artificial chemical synthesis is modified, distribution of cationic amino acid is optimized, and the antibacterial activity of the antibacterial peptide is remarkably improved. The antibacterial peptide cd77AHP-2 has a remarkable antibacterial effect on acinetobacter baumannii which are gram-negative bacteria and multi-drug resistant acinetobacter baumannii, and the antibacterial peptide cd77AHP-2 has a remarkable antibacterial effect on the acinetobacter baumannii which are gram-negative bacteria. The antibacterial peptide cd77AHP-2 provided by the invention has relatively low cytotoxicity to human bronchial epithelial cells, and has the potential of preparing a drug for resisting drug-resistant acinetobacter baumannii. The invention provides a novel functional polypeptide for the field of antibacterial peptides, and the novel functional polypeptide has important practical application value.

The invention relates to recombinant III-type humanized collagen and application of a composition containing the same to eyes. The invention provides an application of recombinant III type humanized collagen in preparation of a product for preventing and / or treating eye inflammation, a composition containing the recombinant III type humanized collagen, and an application of the composition in preparation of a product for preventing and / or treating eye inflammation and / or eye dryness. The recombinant III-type humanized collagen and the composition containing the recombinant III-type humanized collagen can obviously promote updating and repairing of corneal epithelial cells, and meanwhile, can inhibit release of inflammatory mediators, enhance eye tissue barriers, enhance tear film stability and relieve eye inflammation and eye dryness.

The invention relates to protein nanoparticles for treating ulcerative colitis as well as a preparation method and application thereof, and relates to the field of nano pharmaceutical preparations. 5-aminosalicylic acid is encapsulated in zein to achieve the purpose of improving the bioavailability of the 5-aminosalicylic acid by preparing protein nanoparticles of a targeted inflammation colon part, mannose grafted hyaluronic acid is used as a stabilizer to be attached to the surfaces of the zein nanoparticles through electrostatic adsorption and hydrogen-bond interaction, and the bioavailability of the 5-aminosalicylic acid is improved. Mannose can be targeted to immune cells through a mannose receptor, and can be cooperated with 5-aminosalicylic acid to treat ulcerative colitis. The hyaluronic acid has the effects of stabilizing the protein nanoparticles and targeting macrophages and intestinal epithelial cell CD44 receptors in ulcerative colitis tissues, so that aggregation of the nanoparticles in the colitis tissues is mediated, the protein nanoparticles have the functions of resisting inflammation, resisting oxidation and repairing barrier injury, and a new research direction is provided for treatment of ulcerative colitis.

The invention discloses an effect of Collagen in relieving vomitoxin injury of bovine rumen epithelial cells by vitamin E, and belongs to the technical field of genetic engineering, the Collagen is COL1A1 protein, COL2A1 protein and COL5A1 protein; the amino acid sequence of the COL1A1 protein is as shown in SEQ ID NO. 19; the amino acid sequence of the COL2A1 protein is as shown in SEQ ID NO. 20; the amino acid sequence of the COL5A1 protein is as shown in SEQ ID NO. 21. According to the effect of Collagen in relieving bovine rumen epithelial cells damaged by vomitoxin through vitamin E, it is found that vitamin E can effectively protect the cell membrane integrity of the bovine rumen epithelial cells and can relieve cell viability decline, oxidative stress, immune and inflammatory reactions and the cell apoptosis rate caused by DON; vitamin E can promote ECM receptor effect and protein digestion and absorption ways by adjusting Collagen protein so as to protect rumen epithelial cells of dairy cows.

The invention discloses a 3D intestinal organ differentiation method based on human pluripotent stem cells and an induction culture medium and application thereof, and relates to the technical field of stem cells. According to a culture medium formula combination, intestinal organs can be differentiated into various cell types such as epithelial cells, neuroendocrine cells and endothelial cells; the method is a key mark for successful differentiation and functional maturation of intestinal organs. According to the 3D intestinal organ differentiation method disclosed by the invention, histological structures such as intestinal crypts are differentiated from intestinal organs generated by differentiation, and the intestinal organs can creep in a maintenance stage, so that the intestinal organs are changed from structural bionics to functional simulation, and the significance of the 3D intestinal organ differentiation method is far better than that of pure morphological simulation. Through a systematic culture medium formula, a clear operation process and a multi-stage induction strategy, the 3D intestinal organ with structural integrity, cell diversity and functional activity is successfully constructed, and the system provides an efficient, reliable and extensible in-vitro model platform for intestinal biological research and related application.

The invention belongs to the technical field of biology, and relates to a biomarker for early diagnosis of non-small cell lung cancer and application of the biomarker. The biomarker comprises a combination of secretory phosphoprotein 1, epithelial cell adhesion molecules and matrix metallopeptidase 14, and / or a combination of coding nucleic acid of the secretory phosphoprotein 1, coding nucleic acid of the epithelial cell adhesion molecules and coding nucleic acid of the matrix metallopeptidase 14. The coding nucleic acid comprises mRNA or cDNA. In a test set, a non-small cell lung cancer circulating tumor cell scoring diagnosis model constructed by taking the biomarker as the characteristic has the diagnosis accuracy of 87.5% and the sensitivity and specificity of 92.5% and 82.5% respectively. Compared with existing clinical tumor indexes, cancer can be found more early, and early screening of the non-small cell lung cancer is facilitated.

The invention provides a homogeneous electrochemical analysis method for exosome detection based on DNA-Pb < 2 + > functional nano-hydrogel and application, and relates to the technical field of biomedical diagnostic analysis method.The homogeneous electrochemical analysis method is constructed based on DNA nano-hydrogel prepared through a rolling circle amplification (RCA) method by combining a G-quadruplex structure and a Pb < 2 + > specific recognition mechanism; an epithelial cell adhesion molecule (EpCAM) on the surface of the exosome is selected as a detection target, the DNA nano-hydrogel is triggered to disintegrate by utilizing specific binding between the EpCAM and an aptamer thereof, then a large number of G-quadruplex structures generated by RCA are exposed, the G-quadruplex structures can be selectively bound with Pb < 2 + > and regulate and control electrochemical signal output, and the detection sensitivity is high. According to the method, a one-pot method, a rapid and efficient detection process is realized, and the whole process is completed within 45 minutes.

The invention relates to application of sea cucumber-derived nano-vesicles in preparation of a medicine for promoting wound repair. The nano-vesicles (SC-EVs) extracted and prepared from sea cucumbers can effectively promote cell migration, scratch repair and tube forming capabilities of human skin epithelial cells (HACAT) and human skin microvascular endothelial cells (HM DEC) and inhibit cell apoptosis, so that the capability of repairing cells is achieved, and particularly the effect of repairing wound surfaces in a high glucose state or diabetes mellitus is achieved. The invention provides a new direction and thought for the application of the sea cucumber-sourced nano vesicles (SC-EVs), provides a brand new drug research and development and clinical treatment direction for wound repair, especially for solving the problem of difficult healing of wounds of patients with high glucose or diabetes, and has extremely high social value and market application prospect.

The invention belongs to the technical field of medical image detection, and particularly relates to an esophageal flora image intelligent detection method for risk prediction of gastroesophageal reflux disease, which comprises the following steps: acquiring flora images and clinical data, and constructing a perception network; quantifying flora displacement characteristics by using image registration; the method comprises the following steps of: extracting flora density, aggregation degree and fluorescence gradient characteristics by combining improved U-Net + + segmentation, fusing flora and epithelial cell lesion characteristics through space-time attention, generating a flora-host association map, constructing a flora dynamic evolution model by utilizing a space-time map convolutional network, predicting Barrett esophageal occurrence probability and flora diffusion trend, and predicting the occurrence probability of the Barrett esophagus. Calculating a lesion risk level through a flora imbalance quantification algorithm; in combination with reflux frequency and pH fluctuation, a flora-environment interaction model is used for simulating a field planting coefficient and correcting parameters, the parameters are transmitted to a diagnosis platform to deduce canceration risks, grading suggestions are triggered, and a visual report is generated. Therefore, the problems of long detection period, weak microscopic analysis capability and the like in the prior art are solved.

A robust nasal organoid culture system and fully characterized 2D and 3D in vitro produced organoids are provided, as well as methods of using the organoids. The nasal organoids comprise a population of differentiated nasal epithelial cells having cellular heterogeneity and molecular markers similar to mature nasal epithelial tissue. Improved methods for producing two-dimensional and three-dimensional nasal organoids are also provided. These methods generally require a two-phase culture system, i.e., amplification and differentiation culture. The provided nasal organoids are suitable for reproducing nasal tissue complexity, for mimicking respiratory diseases, studying barrier function and drug delivery, high throughput drug screening, and assessing the effects of pathogens and environmental toxins on nasal respiratory epithelium.

The invention discloses lactobacillus gasseri capable of improving expression of host antibacterial peptide Cathelicidin and secretory immunoglobulin sIgA and enhancing infection resistance by oral administration and external application and a metagen thereof, and belongs to the technical field of microorganisms. The lactobacillus gasseri disclosed by the invention can be used for promoting the generation of a vaginal epithelial cell antibacterial peptide Cathelicidin; the shedding of vaginal epithelial cells is reduced, the fungal load is reduced, and the generation of vaginal tissue antibacterial peptide CRAMP is improved; the pIgR and immune globulin content of the vaginal tissue is increased; the invention also finds that the lactobacillus gasseri for external use can regulate and control TLR2 (Toll-Like Receptor 2), and further has a good balancing effect on body immunity. Therefore, the lactobacillus gasseri has a huge application prospect in a product for improving the pathogenic bacterium infection resistance of a host, enhancing the self-defense capability and inhibiting the vagina inflammation.

The invention relates to the technical field of image recognition, in particular to an adhesion focus positioning method for an endometriosis rat model, which comprises the following steps of: firstly, adjusting a clustering distance according to color difference between saturation connected domains and a position inertial system, and clustering to obtain a connected domain cluster; due to the fact that the connected domain clusters contain the ectopic glands, the clusters need to be screened to obtain the ectopic glands, the gland probability of each connected domain cluster is obtained according to the characteristic that columnar epithelial cells are distributed on the inner walls of the ectopic glands, and the possibility that each connected domain cluster belongs to the ectopic glands is judged; due to the fact that the ectopic glands are distributed in a concentrated mode, the abnormal probability of the connected domain clusters is obtained through the aggregation of the connected domain clusters with the high gland probability, the possibility that the connected domain clusters belong to the abnormal ectopic glands is further judged, and the focus positioning accuracy of the endometriosis rat model is higher.

The invention belongs to the field of biological medicines, and particularly discloses application of a Ptprj agonist GJ103 in preparation of a medicine for treating acute kidney injury (AKI) induced by cisplatin. In-vivo and in-vitro experiments prove that the GJ103, by activating Ptprj, can significantly down-regulate expression of pro-apoptotic protein Bax and Cleved Caspase-3, up-regulate anti-apoptotic protein Bcl2 and reduce infiltration of inflammatory factors TNF-alpha and IL-6, so that apoptosis and inflammatory response of renal tubular epithelial cells are relieved. In in-vivo experiments, GJ103 (20-40mg / kg / day) can reduce serum creatinine and urea nitrogen levels of cis-platinum model mice and improve pathological injuries such as renal tubule dilatation; in in-vitro experiments, 20-40 [mu] M of GJ103 can inhibit apoptosis of renal tubular epithelial cells and reduce expression of renal injury markers NGAL and Kim-1. The pharmaceutical composition contains GJ103 and a pharmaceutical carrier, the preparation form can be a 4mg / mL injection (the purity is greater than or equal to 99.46%) or an oral preparation, and a new strategy is provided for clinical treatment of cisplatin renal toxicity.

The present invention belongs to the field of genetic engineering and biotechnology, and relates to the screening, construction and application of a modified type of AAV-8 serotype for gene targeting and expression. The modified type of the AAV-8 serotype of the present invention inserts 10 amino acid sequences between the 590th amino acid and the 591st amino acid of the AAV-8 serotype capsid protein sequence as shown in SEQ ID NO.2, wherein the 3rd to 9th amino acids are amino acid sequences obtained by screening. The modified serotype of the present invention targets each layer of the retina, and the fluorescence effect after infection is stronger, and it can be clearly and intuitively observed that the exogenous gene can be efficiently expressed in each layer of the retina of the targeted tissue, including the retinal ganglion cell layer, the inner nuclear layer, the outer nuclear layer, the photoreceptor cell layer and the retinal pigment epithelial cell layer, and has better and more targeted tissue expression than the wild-type serotype when the same amount of virus is used.

The invention discloses lactobacillus rhamnosus for improving thrombus and cerebral apoplexy as well as a product and application thereof, and relates to the technical field of microorganisms. The lactobacillus rhamnosus NHNK-604 disclosed by the invention is preserved in the China Center for Type Culture Collection on March 7, 2024, and the preservation number of the lactobacillus rhamnosus NHNK-604 is CCTCC (China Center for Type Culture Collection) NO: M 2024417. The NHNK-604 has the functions of dissolving thrombus, regulating blood coagulation factors of vascular endothelial cells, reducing inflammation and apoptosis of the vascular endothelial cells, reducing aging damage of cerebral micro-blood endothelial cells and promoting blood-brain barriers. In addition, the thallus biological membrane can increase colonization of mucoprotein and intestinal epithelial cells, and can be used for preparing products for improving thrombus and cerebral apoplexy.

The invention provides a methacrylic anhydride modified sclera extracellular matrix repair material and a curing method thereof, and belongs to the technical field of medical repair materials. The methacrylic anhydride modified sclera extracellular matrix repair material provided by the invention is prepared from the following raw materials: a methacrylic anhydride modified sclera extracellular matrix, methacrylated gelatin, a photoinitiator and a solvent. The sclera extracellular matrix modified by methacrylic anhydride is adopted, methacrylic anhydride contains methacrylic acid, double bonds can be introduced, the sclera extracellular matrix has the photo-initiation polymerization capacity, and in-situ gelling can be carried out at sclera and cornea damage positions under the action of a photoinitiator; the sclera extracellular matrix has good biocompatibility and histocompatibility, so that sclera matrix cells and corneal epithelial cells are adhered and proliferated, and the sutureless repair is realized; the methacrylated gelatin can provide a photo-crosslinking gelatin network under the action of a photoinitiator, so that cell adhesion and proliferation can be promoted, and repair is realized.

The invention discloses application of tannic acid combined triazole medicines in preparation of medicines for treating diseases caused by fungi, and belongs to the technical field of antifungal. A series of drug sensitive tests show that tannic acid lower than 3 [mu] g / ml has no influence on the activity of human vaginal epithelial cells, and after the tannic acid is combined with fluconazole, the tannic acid can significantly inhibit the growth activity of drug-resistant candida (including drug-resistant candida albicans and drug-resistant candida glabrata). In view of the natural property, wide source and low toxicity of tannic acid, the invention provides a new antifungal treatment strategy, and the tannic acid has important clinical application value for treating infection (such as vaginal candidiasis) caused by drug-resistant fungi, especially under the condition that the existing antifungal drugs are poor in effect. Therefore, the tannic acid combined triazole medicine can be used for preparing the medicine for treating diseases caused by fungi.

The invention belongs to the technical field of biomedicine, and discloses application of histone lactic acid modification as a target spot in preparation of a medicine for preventing or treating chronic obstructive pulmonary diseases, in particular to lactic acid modification on 18th lysine residues of histone 3, and the expression level of ATM protein in airway epithelial cells is up-regulated through the histone lactic acid modification, so that the chronic obstructive pulmonary diseases can be prevented or treated. The expression of cell senescence key genes is promoted, so that the senescence phenotype of airway epithelial cells is aggravated, and the airway epithelial cells participate in the disease process of mediating the chronic obstructive pulmonary disease. The discovery provides a new therapeutic target for the chronic obstructive pulmonary disease.

The invention relates to the technical field of biological medicine, in particular to a lactobacillus-sourced extracellular vesicle and application of the lactobacillus-sourced extracellular vesicle in prevention and treatment of necrotizing enterocolitis, the extracellular vesicle is prepared from lactobacillus, the lactobacillus is Lactobacillus rhamnosus GG, the strain is purchased in the American Center for Type Culture Collection, and the preservation number is ATCC 53103. The preparation method of the extracellular vesicles comprises the following steps: carrying out ultracentrifugation on a lactobacillus culture solution, removing thalli, then collecting supernate, carrying out primary microfiltration, taking micro-filtrate, carrying out differential centrifugation, resuspending precipitates by using PBS, then carrying out secondary microfiltration, collecting the micro-filtrate, carrying out density gradient centrifugation, and collecting a 30-45% interface vesicle layer. The invention discloses a synergistic effect mode between intestinal symbiotic flora and intestinal epithelial cell metabolic molecules for the first time, and the discovery is expected to construct a brand-new mechanism normal form for regulating the host intestinal barrier function by flora.

The invention discloses a mucosal epithelial cell targeted oral ROS response type nano-enzyme as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The oral ROS response type nano-enzyme comprises Ce-CDs carbon dots and a betaine polymer, and the betaine polymer is coated on the surfaces of the Ce-CDs carbon dots to form nano-particles; the Ce-CCDs carbon dots are prepared by taking a metal cerium source and chlorogenic acid as raw materials through a pyrolysis method. Through structural innovation and function integration, the prepared nano-enzyme shows outstanding advantages in the aspects of catalytic activity, targeted delivery, collaborative treatment, industrial application and the like, a new technical scheme is provided for efficient and safe treatment of inflammatory bowel diseases, and the nano-enzyme has remarkable technical innovation and clinical application value.

The invention belongs to the field of biological medicine, and particularly relates to an antibacterial peptide for inhibiting staphylococcus aureus and pseudomonas aeruginosa and application of the antibacterial peptide. The antibacterial peptide CAMP648NC is a novel cationic antibacterial peptide, the minimum inhibitory concentrations of the antibacterial peptide CAMP648NC to pathogenic bacteria staphylococcus aureus and pseudomonas aeruginosa are 16 [mu] g / mL and 32 [mu] g / mL respectively, the antibacterial peptide CAMP648NC has extremely low cytotoxicity, and after human skin keratinocytes HaCat and bronchial epithelial cells BEAS-2B are treated by the antibacterial peptide CAMP648NC with the concentration of 128 [mu] g / mL for 24 hours, the survival rates of 110.4% and 87.3% are still kept. Due to the characteristics, the compound shows extremely high medical drug antibacterial value, and alternative medicinal resources are provided for clinically resisting the two human pathogenic bacteria in the future.

The invention relates to application of piRNA as a target spot in preparation of a medicine for treating lung cancer or lung injury caused by tobacco exposure, and belongs to the technical field of biomedicine. The invention provides application of piR-2850767 and / or piR-157618 as a target spot in preparation of a medicine for treating lung cancer or lung injury caused by tobacco exposure, and particularly relates to application of an expression inhibitor of piR-2850767 and / or an overexpression reagent of piR-157618 in preparation of a medicine for treating lung cancer or lung injury caused by tobacco exposure. The inhibitor and the overexpression preparation can cause growth inhibition of lung cancer representative cells A549 and cause apoptosis of the lung cancer representative cells A549, and can recover cell cycle arrest, cell apoptosis, cell proliferation and motor ability decline of lung epithelial cells caused by tobacco exposure as a preventive drug for lung injury caused by tobacco exposure.

The invention belongs to the technical field of preparation of postbiotics, and discloses a preparation method and application of lactic acid bacteria fermented Chinese chestnut protein postbiotics for improving systemic chronic inflammations, Chinese chestnuts are subjected to shelling, grinding and degreasing treatment, and degreased Chinese chestnut powder is obtained; resuspending the degreased Chinese chestnut powder in distilled water, adjusting the pH value, and stirring; performing solid-liquid separation and magnetic stirring; carrying out solid-liquid separation, resuspending and adjusting the pH value; dialyzing to obtain Chinese chestnut protein powder; mixing with glucose powder, and redissolving in distilled water; and mixing with lactic acid bacteria and carrying out aerobic fermentation to obtain the Chinese chestnut protein metaplasm product. The bioactive peptides contained in the Chinese chestnut protein metaplasm prepared by the method have potential anti-inflammatory activity, can effectively inhibit proinflammatory medium secretion of macrophages and intestinal epithelial cells, and improve glucose and lipid metabolism disorder and intestinal barrier function damage related to chronic inflammation of a body. The bioactive peptide contained in the postbiotic product disclosed by the invention has an anti-inflammatory effect.

The invention discloses an anti-neurodegeneration exosome composition as well as a preparation method and application thereof. The anti-neurodegeneration exosome composition is prepared from the following components in parts by mass: 5 to 25 parts of human exfoliated deciduous tooth stem cell exosome, 25 to 85 parts of plant-derived exosome-like nano-vesicles, 12 to 10 parts of ginsenoside Rg, 2 to 10 parts of curcumin and 10 to 20 parts of auxiliary materials. The anti-neurodegeneration exosome composition contains a large amount of cell factors, growth factors, miRNA, mRNAs and other components, is easy to fuse with cell membranes of intestinal epithelial cells, can selectively deliver bioactive substances to recipient cells through a blood-brain barrier, carries out information transmission among different cells, regulates signal transduction among the cells, and has a good anti-neurodegeneration effect. The effects of resisting oxidation, resisting inflammation, resisting aging and the like are achieved.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, those within the respiratory tract, particularly the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The systems may be used to treat pathogens, such as bacteria and viruses, particularly coronaviruses.

The invention relates to double-encapsulated lipid nanoparticles entering brain through nose and a preparation method and application thereof, the double-encapsulated lipid nanoparticles comprise lipid nanoparticles, drugs in the lipid nanoparticles and rana odorata lectin coupled to the surfaces of the lipid nanoparticles, and the drugs comprise hydrophilic drugs and hydrophobic drugs. According to the invention, the rana odorata lectin and the lipid nanoparticles are coupled, and the rana odorata lectin can be specifically combined with L-fucose residues expressed by olfactory epithelial cells, so that the adhesion of the lipid nanoparticles to olfactory epithelium during nasal administration is enhanced, and the brain entering efficiency of the lipid nanoparticles is finally improved. After entering the brain, the lipid nanoparticles respond to diseased regions with high active oxygen content so as to release drugs. In addition, double-drug encapsulation can target different pathogenesis of central nervous system diseases, and the limitation that a traditional treatment drug is single in action target is improved.

The invention discloses a ferroptosis inhibitor and application of the ferroptosis inhibitor in radiation pneumonitis drugs, and relates to the technical field of biological medicines. The specific preparation method comprises the following steps: adding the ferroptosis inhibitor and the auxiliary agent into the solvent, and dissolving to obtain the ferroptosis inhibitor composition; wherein the ferroptosis inhibitor is isoorientin; the auxiliary agent is a glucosamine derivative; the solvent is a serum-free DMEM culture medium. The ferroptosis inhibitor composition prepared by the method provided by the invention can effectively reduce the rise of active oxygen, ferrous ions and malondialdehyde levels of human pulmonary epithelial cells BEAS-2b and mouse pulmonary epithelial cells MLE-12 caused by irradiation, restore cell mitochondrial membrane potential enrichment and inhibit the expression of various inflammatory factors in irradiated cells; therefore, the process of radiation pneumonitis is remarkably improved, and a new medication strategy is provided for research on radiation pneumonitis drugs.

The invention relates to the technical field of cell engineering, and particularly discloses a construction method and application of a sika deer immortalized renal epithelial cell line, and the construction method comprises the following steps: taking renal epithelial primary cells from healthy sika deer renal cortex tissues to obtain primary renal epithelial cells; treating the primary renal epithelial cells with trypsin to obtain a cell suspension; inoculating the cell suspension into a complete culture medium, and transfecting with lentivirus loaded with SV40 large T antigen genes to obtain transfected cells; 3 [mu] g / mL puromycin is applied to the transfected cells for selective culture, so that non-transfected cells are eliminated, and drug-resistant cells are obtained; carrying out continuous passage on the drug-resistant cells for at least 30 generations to obtain the immortalized renal epithelial cell line of the sika deer; according to the invention, through a specific action mechanism (inhibiting a p53 / pRb pathway and blocking cell cycle exit) of the SV40 large T antigen, a proliferation limit caused by inhibition of telomerase activity of primary cells of the cervidae animals is overcome, and a cell resource library capable of realizing continuous passage is established.

The present invention relates to an exogenous target gene expression cassette for delivering an exogenous target gene to the retina, in particular AIPL1 to retinal pigment epithelial cells and photoreceptor cells, comprising an IRBP enhancer sequence, a rhodopsin kinase (RK) promoter sequence and a CAG intron sequence, which are operatively linked, and an exogenous target gene. The present invention also relates to a recombinant adeno-associated viral vector comprising a viral capsid comprising a capsid protein or a capsid protein variant and a viral vector genome comprising an expression cassette encoding for specifically expressing an exogenous target gene in retinal pigment epithelial cells and photoreceptor cells. The recombinant adeno-associated virus vector can be used for relieving or treating retinal degenerative eye diseases by intravitreal administration or subretinal administration.